16 October 2024 US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity.
The USA’s Federal Trade Commission (FTC) says it has filed an amicus brief to address the anticompetitive harm that stems from improperly listed patents in the Food and Drug Administration’s (FDA) publication of “Approved Drug Products with Therapeutic Equivalence Evaluations,” commonly known as the “Orange Book.” 21 November 2023
Italian family-owned drugmaker Chiesi Farmaceutici has added another investigational product to its list of in-licensed investigational meds, as well as the $1.25 billion acquisition of Anglo-Irish firm Amryt Pharma, this year alone. 20 November 2023
Japanese ophthalmology firm Santen Pharmaceutical has received marketing authorization from the European Commission for Catiolanze (cationic emulsion of latanoprost 50μg/mL, STN1013001). 20 November 2023
Aurobindo Pharma subsidiary Acrotech Biopharma has been urged to work with the US Food and Drug Administration (FDA) to swiftly advance a confirmatory trial of the cancer drugs Folotyn (pralatrexate) and Beleodaq (belinostat). 20 November 2023
French independent pharma major Servier presented new data for vorasidenib in IDH-mutant diffuse glioma at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) in Vancouver, Canada, showing that vorasidenib reduced tumor growth as measured by a blinded independent radiology committee. 20 November 2023
Tense negotiations between the UK government and the pharmaceutical industry over a new drug pricing framework have concluded with a far-reaching agreement. 20 November 2023
Bayer shares plunged to their lowest in a decade after the German pharma major said it would discontinue a late-stage trial for a blood-thinning drug for heart disease that had failed to demonstrate efficacy. 20 November 2023
The UK’s largest drugmaker, AstraZeneca, has announced the launch of a new AI-focused digital health solutions company, to be called Evinova. 20 November 2023
Leerink Partners analysts have published a Leerink Healthcare Team report on GLP1s+ (ie, including new drug mechanisms) to potentially transform the healthcare industry. 20 November 2023
The National Institute for Health and Care Excellence (NICE) has issued its Final Draft Guidance (FDG) recommending Jardiance (empagliflozin) as an option for the treatment of eligible adults with chronic kidney disease (CKD) in England and Wales. 17 November 2023
GLP-1 agonists are transforming the way cardiometabolic disorders are treated, with new approvals in obesity opening the door to significant new treatment opportunities. 17 November 2023
The UK’s Competition and Markets Authority (CMA) has clarified the circumstances under which it will not prioritize enforcement action against pharmaceutical companies when they implement a specific ‘negotiation framework’ to make more combination therapies available on the National Health Service (NHS). 17 November 2023
Vision-focused biopharma LENZ Therapeutics and Graphite Bio have entered into a definitive merger agreement to combine the companies in an all-stock transaction. 16 November 2023
Shares of US biopharma CorMedix rose as much as 18% ad closed up 6.4% at $3.33 yesterday, after it revealed that the US Food and Drug Administration (FDA) has approved its DefenCath (taurolidine and heparin). 16 November 2023
Markets have reacted warmly to a radical plan from Theseus Pharmaceuticals to cut costs and potentially put itself up for a sale or merger. 15 November 2023
Gan & Lee Pharmaceuticals as reported that its three investigational drugs - GZR18, GZR4, and GZR101 - achieved positive results in Phase II diabetes trials. 17 October 2024
A new group of British Members of Parliament (MPs) and peers have written to the Chancellor urging her to protect and promote the UK’s world-leading life sciences sector in the government's first Budget, due on October 30. 17 October 2024
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma giant Novartis for a small molecule anti-tumor asset. 17 October 2024
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.